InvestorsHub Logo
Followers 58
Posts 10137
Boards Moderated 1
Alias Born 09/21/2016

Re: tredenwater2 post# 413862

Thursday, 05/04/2023 4:20:20 PM

Thursday, May 04, 2023 4:20:20 PM

Post# of 461923
Lets all pray that AVXL-S1R becomes CNS systems solutions for those people who have been told..."Sorry, no effective treatments are available".
Just another good reason to own AVXL stock...feeling better already.

Tredenwater2

Anavex advantages of Rett Syndrome approval over Arcadia.

1) 100 million dollar voucher and data can be used to help support/submit for Alzheimer’s approval.

2) Anavex has partnered with Rett Syndrome.org and RAM which are worldwide and will help get the word out upon approval thus helping to accelerate sales and market penetration due to superior efficacy and more importantly lack of horrible side affects coupled with liquid formulation, huge!

3) should help accelerate the approval of future Rare disease trials where symptoms overlap. Yes, a few more trials still need to be ran but imo that would be it before prophylactic rare disease use. Dr. Missling has eluded as much as he has picked Rare diseases with a broad range of overlapping symptoms.

4) massive acceleration into a rare disease mini behemoth pharma allowing Anavex to stay independent and grow by funding as many trials as it needs for pipeline expansion.

Cheers

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News